Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Journal of Clinical Oncology.
Times cited: 323
Quantitative analysis of circulating tumor cells as a survival predictor in metastatic castration-resistant prostate cancer: Missing parts in a superb study.
Journal of Pain and Symptom Management.
Times cited: 1
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
Clinical Cancer Research.
Times cited: 1064